ENDEAVOR SPRINT RX CORONARY STENT SYSTEM
Report
- Report Number
- 2953200-2011-00297
- Event Type
- Injury
- Date Received
- February 7, 2011
- Date of Event
- December 3, 2013
- Report Date
- December 12, 2013
- Manufacturer
- MEDTRONIC CARDIOVASCULAR GALWAY
- Product Code
- NIQ
- PMA / PMN Number
- P060033
- Removal / Correction Number
- NA
- Adverse Event
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- BR
- Reporter Occupation
- PHYSICIAN
Narratives
(B)(4). EVALUATION, RESULTS: MI.
RESULTS, CONCLUSION: HAEMORRHAGE. (B)(4).
CONTINUED FROM CONCOMITANT MEDICAL PRODUCTS: LIPID LOWERING DRUGS. (B)(4): DISSECTION. PATIENT'S AGE AT TIME OF EVENT WAS (B)(6) NOT (B)(6) AS REPORTED IN INITIAL REPORT.
DURING INDEX PROCEDURE, THE PATIENT HAD 2 ENDEAVOR SPRINT RAPID EXCHANGE (RX) DRUG-ELUTING STENTS IMPLANTED TO THE MID LAD. DURING IMPLANTATION A DISSECTION OCCURRED. IT IS UNKNOWN HOW THE DISSECTION WAS TREATED. (REF MFR # 9612164-2012-00026)
APPROXIMATELY 36 MONTHS POST INDEX PROCEDURE THE PATIENT WAS HOSPITALIZED DUE TO A GI BLEED. THE PATIENT WAS TREATED WITH MEDICATION AND A TRANSFUSION. ANTIPLATELET MEDICATION WAS STOPPED DUE TO THE EVENT AND RESUMED 4 DAYS POST THE GI BLEED. INVESTIGATOR INDICATED THAT THE REPORTED EVENT WAS NOT RELATED TO THE STUDY DEVICE IT IS REPORTED THAT THE ISSUE IS NOT RESOLVED.
A 3.0 MM DIAMETER X 18 MM LENGTH ENDEAVOR SPRINT RAPID EXCHANGE (RX) DRUG ELUTING CORONARY STENT WAS DEPLOYED IN THE MID LAD OF A PATIENT WITH NO ISSUES REPORTED. IT WAS REPORTED THAT THE PATIENT HAD AN MI ONE DAY POST IMPLANT OF THE RELEVANT STENT. PROLONGED HOSPITALIZATION WAS REQUIRED. NO OTHER CLINICAL SEQUELAE WERE REPORTED.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 1 | ENDEAVOR SPRINT RX CORONARY STENT SYSTEM | NIQ | MEDTRONIC CARDIOVASCULAR GALWAY | NA | 0001031882 |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | 00071 YR | Hospitalization | OMEPRAZOL| DAPT| ASA| BETA, ANGIOTENSIN, CA++ ANTAGONIST| CLOPIDOGREL |